IRF9 antibody (full length)
Quick Overview for IRF9 antibody (full length) (ABIN7878453)
Target
See all IRF9 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- full length
-
Purpose
- IRF9 Antibody / Interferon regulatory factor 9
-
Purification
- Protein A/G affinity
-
Immunogen
- Recombinant full-length human IRF9 protein was used as the immunogen for the IRF9 antibody.
-
Isotype
- IgG2a
-
-
-
-
Application Notes
- Optimal dilution of the IRF9 antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Aliquot the IRF9 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- IRF9 (Interferon Regulatory Factor 9 (IRF9))
-
Alternative Name
- IRF9
-
Background
- Transcription regulatory factor that mediates signaling by type I IFNs (IFN-alpha and IFN-beta). Following type I IFN binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize, associate with IRF9/ISGF3G to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of interferon stimulated genes, which drive the cell in an antiviral state.
-
UniProt
- Q00978
-
Pathways
- JAK-STAT Signaling, Interferon-gamma Pathway, Hepatitis C
Target
-